Clinical Studies on Aortic Aneurysm & Dissection Treatments: A Review

Clinical Studies on Aortic Aneurysm & Dissection Treatments: A Review

I. Introduction

Aortic aneurysms and dissections represent critical cardiovascular conditions characterized by the weakening and potential rupture of the aorta, the body's largest artery. An **aortic aneurysm** involves a localized dilation of the arterial wall, while an **aortic dissection** occurs when a tear in the inner layer of the aorta allows blood to surge between the layers, forcing them apart. Both conditions can be life-threatening, necessitating timely diagnosis and effective management strategies. This comprehensive review aims to synthesize recent clinical studies concerning the diagnosis, medical management, and interventional treatments for aortic aneurysms and dissections. The information presented herein is tailored for both healthcare professionals seeking updated insights and patients endeavoring to understand these complex conditions. The ultimate goal is to highlight advancements and ongoing challenges in the pursuit of improved patient outcomes.

II. Understanding Aortic Aneurysms

A. Pathophysiology and Risk Factors

An abdominal aortic aneurysm (AAA), the most common type, is defined by a permanent, localized arterial dilation affecting all three layers of the aortic wall [1]. In the United States, approximately 200,000 individuals are diagnosed with an AAA annually, with a prevalence ranging from 4% to 8% in the general population. The incidence is notably higher in men and individuals over 65 years of age, with the risk doubling with each successive decade of life [2]. Key risk factors contributing to AAA development include atherosclerosis, chronic inflammation, inherited connective tissue disorders such as Marfan and Ehlers-Danlos syndromes, aortic trauma, and various infections [2].

B. Traditional Surgical Management

Historically, the primary treatment for larger aortic aneurysms has been **open aneurysm repair**. This major surgical procedure involves opening the abdomen or chest, controlling blood flow, excising the aneurysmal segment, and replacing it with a synthetic graft. While effective, open repair is associated with a prolonged hospital stay, often exceeding two weeks, and a recovery period extending over several months [2].

C. Advanced Endovascular Interventions

Significant advancements in minimally invasive techniques have revolutionized aortic aneurysm treatment. **Complex Fenestrated Endovascular Aneurysm Repair (FEVAR)**, developed approximately 30 years ago and routinely performed for the past 15 years, offers a less invasive alternative. FEVAR is particularly beneficial for aneurysms extending into the chest and for patients who are considered high-risk for open surgery due to age or comorbidities [2]. The procedure involves inserting sheaths into the femoral arteries, guiding wires and catheters through the aorta and its branch vessels, and deploying an endograft—a device made of metal and synthetic material—to seal off the aneurysm. The main aortic graft features fenestrations (small openings) and branches that connect to visceral and renal vessels, ensuring vital perfusion to abdominal organs. This approach significantly reduces hospital stay, often to just one or two days [2].

For patients with unique anatomical challenges, **custom endografts** are meticulously designed based on detailed computed tomography (CT) scans. A limited number of specialized centers in the U.S. collaborate with medical device manufacturers to produce these bespoke devices, with the FDA ensuring adherence to stringent standards and manufacturers monitoring long-term performance. Furthermore, innovative approaches like the **Physician-Modified Endovascular Graft (PMEG)**, authorized by the FDA for investigational device exemption (PS-IDE) research trials, allow surgeons to modify stock endografts in situ, providing a rapid, personalized solution for urgent cases where waiting for a custom-built device is not feasible [2]. These advancements underscore a commitment to expanding treatment options and improving outcomes for a broader patient population.

D. Pharmacological Management of Aortic Aneurysms

The quest for effective pharmacological treatments to halt or reverse AAA progression remains an active area of research. Currently, no single drug has definitively demonstrated the ability to inhibit aneurysm dilation [3]. However, ongoing clinical trials are exploring various drug classes, including antibiotics, antihypertensive agents, hypolipidemic drugs (statins), and hypoglycemic medications (metformin) [3].

Recent studies suggest potential benefits from existing medications in mitigating AAA progression:

• **Statins:** These lipid-lowering agents have been associated with a reduction in the risk of AAA rupture and improved mortality rates in patients with ruptured AAAs. They may also contribute to slowing the aneurysm's expansion rate [3].
• **Metformin:** This antidiabetic medication has shown promise in reducing the expansion rate and rupture risk of AAAs, as well as decreasing perioperative mortality [3].
• **Aspirin:** Antiplatelet therapy with aspirin has been linked to a slower progression of abdominal aortic aneurysms, particularly in male patients and non-smokers [3].

Innovative research, such as the Phase II/III stAAAble clinical trial, is investigating targeted drug delivery mechanisms to stabilize the aortic wall and slow growth in small AAAs, representing a promising frontier in pharmacological intervention [2].

III. Understanding Aortic Dissections

A. Pathophysiology and Classification

Aortic dissection is a catastrophic event characterized by a tear in the intimal layer of the aorta, leading to the separation of the aortic wall layers. This creates a false lumen through which blood flows, compromising true lumen perfusion and potentially leading to organ ischemia or rupture. Immediate stabilization is paramount in managing acute aortic dissection [4].

B. Surgical and Endovascular Management

Acute Type A aortic dissection, involving the ascending aorta, typically necessitates immediate surgical intervention due to its high mortality risk. This usually involves open surgical repair to replace the dissected segment of the aorta [4].

For **Stanford Type B aortic dissection**, which affects the descending aorta, **Thoracic Endovascular Aortic Repair (TEVAR)** has emerged as a primary treatment modality. TEVAR involves the deployment of a stent graft within the aorta to cover the intimal tear, redirect blood flow into the true lumen, and promote false lumen thrombosis. This minimally invasive approach has demonstrated favorable outcomes for many patients [4].

However, endovascular treatment for **Stanford Type A aortic dissection (TAAD)** remains a formidable challenge. The anatomical complexities of the aortic root and ascending aorta, coupled with unique hemodynamic features, present significant hurdles. Challenges include the substantial anatomical variability (e.g., involvement of coronary arteries and aortic valve), the need for novel grafts that conform to complex anatomy, the integration of endovascular stents with valve interventions, and the maintenance of long-term coronary artery patency. Physiological factors, such as the aortic root's complex multidimensional motion during the cardiac cycle, further complicate graft stability and can impact coronary artery hemodynamics [5]. Currently, an ideal endovascular solution or commercialized graft for TAAD is not yet widely available [5].

C. Pharmacological Management of Aortic Dissections

The pharmacological management of aortic dissection is critical for stabilizing patients and preventing disease progression. The cornerstone of medical therapy involves strict control of blood pressure and heart rate to reduce aortic shear stress and minimize the risk of further dissection or rupture [4].

• **Beta-blockers:** Traditionally, beta-blockers have been considered essential for their role in reducing heart rate and blood pressure, thereby decreasing aortic wall stress. They have been associated with improved outcomes in various types of aortic dissection patients, whether managed operatively or non-operatively. However, recent studies, including one published in the *Journal of the American Heart Association* in June 2025, suggest an evolving understanding of their comparative effectiveness, indicating that beta-blocker use might not significantly reduce AD risk or improve outcomes compared to other antihypertensive agents in all survivors of AD [6]. This highlights the need for individualized treatment approaches.
• **Statins:** Statin treatment has been linked to favorable long-term outcomes in medically managed aortic dissection patients, potentially due to their pleiotropic effects beyond lipid lowering, such as anti-inflammatory properties [7].
• **Antihypertensives:** A range of antihypertensive agents are employed to achieve aggressive blood pressure control, a vital component in preventing dissection propagation and rupture [4].
• **Analgesia:** Intravenous morphine sulfate is frequently administered to manage pain and anxiety, which can exacerbate tachycardia and hypertension, thereby indirectly contributing to aortic protection and patient stabilization [4].

Ongoing clinical trials, such as the IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (NCT06087029), are investigating the efficacy of an upfront invasive strategy combining TEVAR with medical therapy to reduce adverse events in specific aortic dissection types [8]. Furthermore, the implementation of protocolized management strategies for acute Type B aortic dissections has demonstrated improvements in the success rates of nonoperative treatments and a reduction in disease progression [9]. These efforts underscore a continuous drive towards refining pharmacological and interventional strategies for aortic dissection.

IV. Future Directions in Aortic Disease Treatment

The landscape of aortic disease treatment is continuously evolving, driven by ongoing research and technological innovation. Future directions are likely to focus on:

• **Personalized Medicine Approaches:** Tailoring treatment strategies based on individual patient genetics, anatomy, and risk profiles to optimize outcomes and minimize adverse events.
• **Novel Drug Delivery Mechanisms:** Developing targeted therapies that deliver pharmacological agents directly to the aortic wall, as exemplified by the stAAAble clinical trial, to enhance efficacy and reduce systemic side effects.
• **Advancements in Endovascular Technologies:** Continued refinement of stent graft designs, materials, and deployment techniques to address complex anatomies, particularly in challenging areas like the ascending aorta and aortic arch.
• **Importance of Multidisciplinary Teams:** Emphasizing collaborative care involving vascular surgeons, cardiologists, radiologists, geneticists, and other specialists to provide comprehensive and integrated patient management.

V. Conclusion

Clinical studies on aortic aneurysm and dissection treatments reveal a dynamic field marked by significant progress and persistent challenges. While traditional open surgical repair remains a cornerstone, the advent of minimally invasive endovascular techniques like FEVAR and TEVAR has expanded treatment options, particularly for high-risk patients. Pharmacological management, though lacking a definitive pharmacological agent to halt progression, shows promise with existing medications like statins, metformin, and aspirin, and through targeted drug delivery research. The ongoing pursuit of personalized medicine, novel drug delivery systems, and advanced endovascular technologies promises further improvements in patient care. Continued research and collaborative efforts are essential to address the remaining complexities and enhance the long-term prognosis for individuals affected by these formidable cardiovascular diseases.

VI. Disclaimer

**IMPORTANT DISCLAIMER:** This blog post is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. The information provided herein is based on current clinical studies and research but should not be used as a substitute for professional medical judgment.

VII. References

[1] Chen, J., Hu, L., & Liu, Z. (2024). *Medical treatments for abdominal aortic aneurysm: an overview of clinical trials*. Expert Opinion on Investigational Drugs, 33(9), 979-992. [https://www.tandfonline.com/doi/full/10.1080/13543784.2024.2377747](https://www.tandfonline.com/doi/full/10.1080/13543784.2024.2377747)

[2] University of Utah Health. (2025, February 19). *Innovative Approaches to Aortic Aneurysm Treatment*. [https://medicine.utah.edu/surgery/cardiothoracic/news/2025/02/innovative-approaches-aortic-aneurysm-treatment](https://medicine.utah.edu/surgery/cardiothoracic/news/2025/02/innovative-approaches-aortic-aneurysm-treatment)

[3] Su, Z., et al. (2022). *Pharmacotherapy in Clinical Trials for Abdominal Aortic Aneurysm*. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9465599/](https://pmc.ncbi.nlm.nih.gov/articles/PMC9465599/)

[4] Belyaev, A. M. (2025). *A Comprehensive Review of Acute Type A Aortic Dissection*. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12593736/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12593736/)

[5] Xiao, Y., Zhang, Y., Li, H., & Guo, Y. (2025). *Research progress on endovascular treatment of Stanford Type A aortic dissection*. PMC. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12443735/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12443735/)

[6] American Heart Association. (2025, June 11). *Beta Blockers as Primary and Secondary Prevention for Aortic Dissection*. Journal of the American Heart Association. [https://www.ahajournals.org/doi/10.1161/JAHA.124.040149](https://www.ahajournals.org/doi/10.1161/JAHA.124.040149)

[7] Smedberg, C., Hultgren, R., Leander, K., & Steuer, J. (2022). *Pharmacological treatment in patients with aortic dissection*. Open Heart, 9(2), e002082. [https://openheart.bmj.com/content/9/2/e002082](https://openheart.bmj.com/content/9/2/e002082)

[8] ClinicalTrials.gov. (N.D.). *IMPRoving Outcomes in Vascular DisEase - Aortic Dissection*. [https://clinicaltrials.gov/study/NCT06087029](https://clinicaltrials.gov/study/NCT06087029)

[9] Afifi, R. O. (2024). *A review of management strategies for type B aortic dissection*. ScienceDirect. [https://www.sciencedirect.com/science/article/pii/S0895796724000243](https://www.sciencedirect.com/science/article/pii/S0895796724000243)